Weekly shot shows promise for controlling severe bleeding disorder

NCT ID NCT04161495

Completed Disease control Sponsor: Bioverativ, a Sanofi company Source: ClinicalTrials.gov ↗

Summary

This study tested a new long-acting treatment called BIVV001 for people with severe Hemophilia A, a condition where blood doesn't clot properly. The goal was to see if a single weekly injection could safely prevent bleeding episodes and treat bleeds when they happen. The trial involved 159 participants aged 12 and older who had previously been treated for Hemophilia A.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Investigational Site Number 121

Perth, Australia
Investigational Site Number 122

Sydney, Australia
Investigational Site Number 136

Buenos Aires, Argentina
Investigational Site Number 137

Buenos Aires, Argentina
Investigational Site Number 139

Mendoza, Argentina
Investigational Site Number 161

Brussels, Belgium
Investigational Site Number 171

Plovdiv, Bulgaria
Investigational Site Number 172

Sofia, Bulgaria
Investigational Site Number 181

Campinas, Brazil
Investigational Site Number 202

Hamilton, Canada
Investigational Site Number 205

Hamilton, Canada
Investigational Site Number 281

Brest, France
Investigational Site Number 282

Lyon, France
Investigational Site Number 283

Lille, France
Investigational Site Number 284

Marseille, France
Investigational Site Number 302

Bonn, Germany
Investigational Site Number 303

Frankfurt, Germany
Investigational Site Number 304

Berlin, Germany
Investigational Site Number 312

Budapest, Hungary
Investigational Site Number 314

Debrecen, Hungary
Investigational Site Number 321

Athens, Greece
Investigational Site Number 401

Vicenza, Italy
Investigational Site Number 402

Milan, Italy
Investigational Site Number 421

Tokyo, Japan
Investigational Site Number 422

Nara, Japan
Investigational Site Number 423

Kitakyushu, Japan
Investigational Site Number 424

Tokyo, Japan
Investigational Site Number 425

Nagoya, Japan
Investigational Site Number 426

Kawasaki, Japan
Investigational Site Number 435

Durango, Mexico
Investigational Site Number 521

Madrid, Spain
Investigational Site Number 531

Chang-hua, Taiwan
Investigational Site Number 532

Taipei, Taiwan
Investigational Site Number 581

Basingstoke, United Kingdom
Investigational Site Number 581

London, United Kingdom
Investigational Site Number 600

Seoul, South Korea
Investigational Site Number 601

Seoul, South Korea
Investigational Site Number 603

Daegu, South Korea
Investigational Site Number 641

Utrecht, Netherlands
Investigational Site Number 902

Seattle, Washington, 98101-3932, United States
Investigational Site Number 906

Las Vegas, Nevada, 89113, United States
Investigational Site Number 908

Lansing, Michigan, 48824, United States
Investigational Site Number 911

San Diego, California, 92121, United States
Investigational Site Number 917

Gainesville, Florida, 32610, United States
Investigational Site Number 919

Ann Arbor, Michigan, 48109, United States
Investigational Site Number 920

Los Angeles, California, 90007-2664, United States
Investigational Site Number 921

Los Angeles, California, 90027, United States

Conditions

Explore the condition pages connected to this study.

FACTOR VIII DEFICIENCY